Currently, multiple myeloma is not yet considered a curable disease. Despite the recent
advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 …

Introduction: TG02 is an orally-bioavailable, multikinase inhibitor where the primary
mechanism of action is through CDK9-dependent depletion of oncoproteins such as Mcl-1 …

The emergence of new drugs is a major feature of the treatment history of multiple myeloma
(MM), which also reflects the current incurability of MM. As a unique member of cyclin …

Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …

* Correspondence to: Ki-Young Lee; Email: kylee@ ucalgary. ca Submitted: 07/30/12;
Accepted: 08/20/12 http://dx. doi. org/10.4161/cc. 21886 investigate the link between the …

Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most
common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play …

Introduction: Multiple myeloma (MM) is characterized by the high tendency to relapse and
develop drug resistance. Areas covered: This review focused on the main novel targets …

Purpose SNS-032 is a highly selective and potent inhibitor of cyclin-dependent kinases
(Cdks) 2, 7, and 9, with in vitro growth inhibitory effects and ability to induce apoptosis in …

Purpose: To analyze the antimyeloma potential of TG02, an ERK5/CDK inhibitory drug.
Experimental Design: Utilizing different multiple myeloma cell lines we determined the effect …

Objective We investigate safety and efficacy in common clinical practice of the combination
of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the …